169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)35182-6
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Clinically Compliant Spatial and Temporal Imaging of Chimeric Antigen Receptor T-Cells

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression Upon Drug Administration

Cancer immunology research
Cancer ResearchImmunology
2016English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2019English

Characterization of Clinical Grade CD19 Chimeric Antigen Receptor T Cells Produced Using Automated CliniMACS Prodigy System

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Genetically Engineered T Cells Expressing a HER2-specific Chimeric Receptor Mediate Antigen-Specific Tumor Regression

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy